218285-65-5

Upstream product

• 218285-61-1 (R)-N-Benzyloxy-2-hydroxymethyl-3-phenyl-propionamide 
• 123802-80-2 (R)-2-hydroxymethyl-3-phenylpropionic acid 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 136159-65-4 (R)-4-benzyl-3-(3-phenyl-propionyl)-oxazolidin-2-one 
• 123803-51-0 2R-benzyl-3-benzyloxypropanoic acid 
• 220805-30-1 (S)-4-Benzyl-3-((R)-2-benzyloxymethyl-3-phenyl-propionyl)-oxazolidin-2-one 
• 709673-94-9 (R)-2-benzyl-3-hydroxypropanoic acid methyl ester 

Downstream Products

• 1354899-35-6 (S)-2-[(R)-2-benzyl-3-(formyl-hydroxy-amino)-propionylamino]-3,3,N-trimethyl-butyramide 
• 1354899-38-9 C₁₈H₂₇N₃O₄ 
• 1354899-39-0 (R)-2-benzyl-3-(formyl-hydroxy-amino)-N-[(S)-1-methylcarbamoyl-2-phenyl-ethyl]-propionamide 
• 944030-55-1 C₁₈H₁₉NO₄ 
• 183182-07-2 (R)-α-benzyl-β-aminopropanoic acid 
• 748127-65-3 methyl 2-[(benzyloxyamino)methyl]-3-phenylpropionate 
• 197902-88-8 (R)-2-(Benzyloxyamino-methyl)-3-phenyl-propionic acid 
• 440679-76-5 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-N-((S)-1-hydroxy-2-oxo-azepan-3-yl)-3-phenyl-propionamide 
• 440679-75-4 (R)-2-(Benzyloxyamino-methyl)-N-((S)-1-hydroxy-2-oxo-azepan-3-yl)-3-phenyl-propionamide 
• 440679-71-0 (R)-2-[(Formyl-hydroxy-amino)-methyl]-N-((S)-1-hydroxy-2-oxo-azepan-3-yl)-3-phenyl-propionamide 

Relevant academic research and scientific papers

Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1

Bone Morphogenetic Protein 1 (BMP1) inhibition is a potential method for treating fibrosis because BMP1, a member of the zinc metalloprotease family, is required to convert pro-collagen to collagen. A novel class of reverse hydroxamate BMP1 inhibitors was

Inhibition of invasion and capillary-like tube formation by retrohydroxamate-based MMP inhibitors

Matrix metalloproteinases (MMPs), a family of zinc-containing endopeptidases, participate in many normal processes such as embryonic development and wound repair, and in many pathological situations such as cancer, atherosclerosis, and arthritis. Peptidomimetic MMP inhibitors were designed and synthesized with Nformylhydroxylamine (retrohydroxamate) as a zinc-binding group and various side chains on the α, P1′, and P2′ positions. Using in vitro MMP assays with purified MMPs (MMP-1, MMP-2, MMP-3, MMP-9, and MMP-14) and fluorogenic peptide substrates, it was found that compounds 2d and 2g selectively inhibit gelatinases (MMP-2 and MMP-9) and interstitial collagenase (MMP-1). They also inhibited the chemo-invasion of fibrosarcoma HT-1080 cells and tube formation of human umbilical vascular endothelial cells in a dosedependent manner. Our results suggest that retrohydroxamate-based MMP inhibitors, especially compounds 2d and 2g, have the potential to be used as therapeutic drugs for cancer and other MMP-related diseases.

Synthesis and Biological Activity of Hydroxamic Acid-Derived Vasopeptidase Inhibitor Analogues

(Equation Presented) Syntheses of novel hydroxamic acid-derived azepinones containing pendant mercaptoacyl groups or formyl hydroxamates are described. These new analogues of therapeutically important ACE and NEP inhibitors include unprecedented changes a

A practical method for the conversion of β-hydroxy carboxylic acids into the corresponding β-amino acids

Optically active α- or β-substituted βamino acids were synthesized from the corresponding β-hydroxy acids in 4 steps in excellent yield. Stereochemistry was retained at the α-position and reversed at the β-position during the conversion.